Sequenom Announces Global Certified Service Provider Program

         Sequenom Announces Global Certified Service Provider Program

PR Newswire

SAN DIEGO, Sept. 18, 2013

SAN DIEGO, Sept. 18, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a
life sciences company providing innovative diagnostic testing and genetic
analysis solutions, today announced a Certified Service Provider (CSP) program
for the technical certification of selected laboratories offering research
services using the Sequenom research-use-only MassARRAY^® System.
Certifications cover the major research applications of the MassARRAY System,
including iPLEX^® genotyping, OncoCarta™ somatic mutation profiling, ADME PGx,
and EpiTyper^® DNA methylation analysis.

"The use of the MassARRAY System in clinical and translational research
continues to grow," said Michael Monko, Sequenom's Senior Vice President for
Genetic Analysis. "Clinical and translational researchers require the greatest
level of confidence in their data, and this program provides assurance in the
quality of the work generated by our network of highly experienced certified
providers."

The certifications have been awarded to the McGill University and Genome
Quebec Innovation Centre in Montreal, Canada, Knight Diagnostic Laboratories
at Oregon Health & Science University, and GeneWorks in Adelaide, Australia.
Additional institutions have included The Clinical Genomics Centre in Toronto,
Canada, Karolinska University Hospital in Sweden, NewGene in Newcastle, UK,
DNA LandMarks (a plant and animal genomics company and subsidiary of BASF)
based in Quebec, Canada, as well as several providers based in Asia.

"We are delighted to partner with Sequenom, and this certification confirms
the high-quality standards we have implemented at the Innovation Centre over
the years for our sequencing and genotyping services.We are especially proud
of this CSP certification because we participated in the creation of the
program and its implementation," said Daniel Tessier, Vice President,
Technology Centres at Genome Quebec.

Sequenom's MassARRAY System is utilized by biomedical researchers worldwide to
measure genetic variations that occur normally or in association with diseases
including cancer. The MALDI-TOF based mass spectrometry technology enables
scientists to utilize highly specific and sensitive pre-designed or
custom-made research use assay panels for several key types of genomic
markers, including single nucleotide polymorphisms, somatic mutations, copy
number variations, gene expression, and DNA methylation.

For additional information, visit www.sequenom.com

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to
improving healthcare through revolutionary genetic analysis solutions.
Sequenom develops innovative technology, products and diagnostic tests that
target and serve discovery and clinical research, and molecular diagnostics
markets. The company was founded in 1994 and is headquartered in San Diego,
California. Sequenom maintains a Web site at http://www.sequenom.com to which
Sequenom regularly posts copies of its press releases as well as additional
information about Sequenom. Interested persons can subscribe on the Sequenom
Web site to email alerts or RSS feeds that are sent automatically when
Sequenom issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the Web site.

SEQUENOM^®, MassARRAY^®, iPLEX^®. EpiTyper^® and OncoCarta™ are registered
trademarks of Sequenom, Inc.

Except for the historical information contained herein, the matters set forth
in this press release, including statements regarding growth of the use of the
MassARRAY system in clinical and translational research, the impact, benefits
or results of using the MassARRAY system, and Sequenom's commitment to
improving healthcare through revolutionary genetic analysis solutions, are
forward-looking statements within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause actual
results to differ materially, including the risks and uncertainties associated
with market demand for and acceptance and use of technology and tests such as
the MaterniT21 PLUS test, reliance upon the collaborative efforts of other
parties such as, without limitation, healthcare providers, international
distributors and licensees, the Company or third parties obtaining or
maintaining regulatory approvals that impact the Company's business,
government regulation particularly with respect to diagnostic products and
laboratory developed tests, publication processes, the performance of designed
product enhancements, the Company's ability to develop and commercialize
technologies and products, particularly new technologies such as noninvasive
prenatal diagnostics, laboratory developed tests, and genetic analysis
platforms, the Company's financial position, the Company's ability to manage
its existing cash resources or raise additional cash resources, competition,
intellectual property protection and intellectual property rights of others,
litigation involving the Company, and other risks detailed from time to time
in the Company's most recently filed Quarterly Report on Form 10-Q for the
quarter ended June 30, 2013, its most recently filed reports on Form 8-K, and
its most recently filed Annual Report on Form 10-K, and other documents
subsequently filed with or furnished to the Securities and Exchange
Commission. These forward-looking statements are based on current information
that may change and you are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. All forward-looking statements are qualified in their entirety by
this cautionary statement, and the Company undertakes no obligation to revise
or update any forward-looking statement to reflect events or circumstances
after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Website: http://www.sequenom.com
Contact: Paul Maier, CFO, Sequenom, Inc., 858-202-9028,
investorrelations@sequenom.com; Rachel Kennedy, Media Contact, Chandler Chicco
Agency, 858-449-9575, rkennedy@chandlerchiccocompanies.com